LearnGlossaryMarketStocksSuperinvestorsSign in

RZLT

Rezolute, Inc.

Healthcare · $379M market cap

Verdict

We can't put a fair value on RZLT right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-22.3% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-59.7%✗

Follow RZLT

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 2, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Karnawat Sunil Ratilal

Chief Commercial Officer · 2026-09-02

Tax withholding

$10K

About Rezolute, Inc.

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works